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AnatomicalSevarityof CoronaryArteryDieeasaand
DiastolicBloodPresaurein HypeftenaivaPatients
withAnginaPectoris
N. Hasebe, S. Kido, A. Ido, K. Kikuchl. Dept.of /nt.Med.,Aa&rikawva
MedicalCollege,Aaahikawa,Japan
There has been much debate on the issue of the J-shaped curve in therapy
of hypertensive patients (HT), especially those with coronary artery disease
(CAD).We examined whether the treated levels of diastolic blood pressura
(DBP) played a crucial role in the J-shaped curve, even considering the
anatomical severity of CAD, i.e., the numbar of diaeased vessels and the
degree of narrowing, in HT with angina pactoris (AP). The enrolled 234 HT
with AP, 148 males and 86 females, mean age of 64 yeare, all of whose
coronary lesions were confirmed by coronary angiography,were followed for
up to 9.5 yeare (mean 2.9 years). 115 patients with coronafy events such as
coronary intervention, myocardial infarction and cardiovascular death, had
significantly greatar severity of CAD mmparad to 119 event-free patients.
Mora interestingly, tha lower the DBP below 85 mmHg the greater was the
eaverity of CAD (Tabla). However,there were no significant differences in tha
incidence of coronary events on either side of the treated DBP of 85 mmHg.
Onlythesubgroup f2alow65mmH9t whichdemonstrated thegreateetseverfty
of CAD, showed a higher incidence of events compared to other levels of
DBP.
DBP(mmHg) 65. 65-s5 85-104 105<
Event Incidsncs(%) 82” 48 49 50
CAD Severily Indsx 13r 115” 6s 100
(value is mean, “p c 0.05vs DBP of 86-104)
The concept “the lower tha DBP the worse the prognosis” might not be
caused strictly by the Iavel of DBP itself but depend rather on the severity of
CAD in HT with angina pectoria.
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1754-31Le~ventri~u,arD,as~o,i~~i,,in9in~e,ationto
DiaetolicBloodPreasureinTreatedHypertensives
withandwithoutIschaemia;A Testof the‘J’Curve
Theory
LF. Islim’z, Cr.G.Beavers*, P.Clarkeon J. Gupta2, M. Ebanka’,
K. Osman 1, S.P. Singh R.D. Wataonl. CatdiobgyCityHospital,
Birmingham,UK,2UniversityDepartmentofMedicine,CilyHospital,
Birmingham,UK
The observation of a J shaped relation between mortality and diastolic blood
pressure (DBP) has not bean aatisfactorflyexplained. One piausibleexplana-
tion is that impaired Ieftventricular diastolic filling (LVD) may hinder coronary
blood flow which may increasa the risk in hypertensive (HT) patients with
coronary heart disease (CHD). Therefore LVD filling was explored in HT
patients with and without CHD.
Treated HT patients without history of CHD; n =37 were compared with
consecutive HTpatientswith angiographically provan CHD; n =26. LVDfilling
was determined by transmittal Doppler flow echocardiography to detect the
ratio between early (E) and late atrial (A) components (WA); it has been
suggested that the smaller the ratio, the worse LVD filling. Bleed pressure
was measured simultaneously. E/A ratio was correlated with DBP in the two
groups, subdivided into patients with DBP above and below 85 mmHg.
Patients with CHD had significantly lower E/A ratio (0.97, 0.87-1.02)
mmpared with those without (1.15, 1.02-1.26); P = 0.036. As shown in
tha table there was significant inversecorrelation between E/A ratio in the
subgroup who had DBP =-85 mmHg among those with CHD. No correlation
was found among othar subgroups.
Subgroup HypsrfensiveswithoutCHD HypsrfsnsivsswithCHD
rvalus P Vslus r valus P valus
>85 mmHg -0.23 0.25 –0.M 0.024
s 65 mmHg +0.64 0.11 +0.05 O.ea
CHDgroup, n =26(s85= 14, >85= 12): NOn-CHDgrOuPin = 36 (s85= 10, >85=28)
We mnclude that LVDfilling was influenced by DBP only in patients with
CHD who had DBP > S5mmHg and thus filling would tend to be improved at
DBP around 85 mmHg and reduced at higher values. Contrary tothe J cutve
theory, DBPs 85 mmHg was not associated with worsening of LVD filling.
This suggests that unduacaution inadministretion of hypotensiveantianginal
agents in HT patients with CHD may be misplaced.
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DirectEvidenceof ImpairedCardiacSympathetic
—fnnervationinEssentialHypertensionWithLeft
VentricularHypertrophy
T. Kuwahara, M. Hamada, 0. Sasaki, T. Otauka, S. Ikada, H. Hashida,
Y. Hara, K. Kodama, Y. Shigematsu, K. Hiwada. .EhimeUniversi~Ehime,
Japan
To investigate cardiac sympathetic netvous activity in essential hyperten-
sion (EHT) with left ventricular hypertrophy (LVH), we performed I-123
metaiodobenzylguanidine (MIBG) myocardial scintigraphy in 42 patients with
EHTand 17normotensive control (NC) subjects. Heart-to-medtastinum MIBG
atiivity ratio (H/M) on both the earfy and dalayed images and myocardial
washout rate (WR) were calculated on the planar image. Regional MIBG
uptake were evaluated as a percent of maximum at tha fiva segments on the
delayed polar map display. Left ventricular mass index (LVMI) was eohooar-
diographicelly determined. EHT patiants were classified into the two groups
according to LVMI: non-LVH (n = 19, LVMI less than or equal to mean value
+ 2SD of LVMI in the NC) and LVH (n = 23, LVMI greater than mean value +
2SD of LVMI in the NC).
LVMI (g/m2) H/M (early) WM (delayed) WR (%)
NC 89+ 18 2,2 * 0.3 2.4 + 0.2 37+ 5
non-LVH 80& 13 2,3 + 0.3 2.4 & 0.4 ii: i
LVH 166 l S3”t 2,0 + 0.3” 2.0 * o.4*t 44 i 6*t
*p <0.01 vs non-LVH,tp <0.0005 vs NC.
Regional MIBG uptake were significantly reduced in the inferior and lateral
regions in the LVH (inferior and lateral; 73+8% and 66 + IIYo, respedively,
p <0.05 vs NC). The H/M correlated inveraely with LVMI (aarly and delayed
image; r = 0.55, p c 0.0005 and r = 0.64, p < 0.0001, respactivaly) and
WR correlated positively LVMI (r= 0.57, p e 0.0001) in patienta with EHT.
We concluded that cardiac sympathetic nerve innervation was impaired in
the inferior and lateral regions in EHT with LVH, and EHT patients showed
decreased MIBG accumulation and an.increased WR in proportion to the
degree of left ventricular hypertrophy.
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El7545 MalignantHypertensioninWomenofChildbearingAga:Relationshipto PreviousHistoryof
Hypertensionin PregnancyandContraceptivePill
Use
G.Y.H. Lip, M. Beevers, D.G. Beevers. UniversityDepartmentof Medicine,
CifyHospita/,Birmingham,England
Previous studies have suggestad that one-third of women of childbearing
age who develop malignant phase hypertension (MHT) are likely to be taking
oral contraceptives (OC).To examine this relationship further, we studied 104
women with MHT: 39 of thase (mean age 34.9 years, s.d. 6.0) were of child-
bearing age at presentation (arbitrarily defined as age 15-44 years). None
of the 65 women agad >45 years were taking OC or other sex hormones.
Of the 39 youngar women, 22 had a histoty of hypertension in pregnancy
(Group 1), and 3 of these also had a history of DC-induced hypertension;
none were pregnant, but one was taking the OC at presentation with MHT.
These 22 women were compared with those with no history of hypertension
in pregnancy (Group 2, n = 17):
Group1 Group2
Whites:Blacke:Asians 12:6:4 10:4:3
Age (years) 34.5 (7.8) 35,5 (8.3)
Priorhypertension(mths) 3S.2 (4S.5) 9.5 (21.2)”
SyatolicBPatprseentstion(mmHg) 235.7(32.7) 235.2 (29.4)
DiastolicBP at presentation(mmHg) 147,9 (16,5) 153.7 (22.9)
Serum ursaat preaentetion(mmoVl) 10,7 (8.4) a.4 (5.s)
Serum creatinineat prsaOnfstlon(pmo!Jl) 189 (156) 210 (256)
SystolicBPatfoilow-up (mmHg) 171.0 (39,2) 165.0 (38.3)
DiastolicBP at follow-up(mmHg) 105.2 (17.9) 105.1 (20.5)
Serum urea at follow-up(mmoffl) 20.8 (22.5) 7.8 (4,7)*
Serum creatine at follow-up(KmO!Jl) 464 (614) 181 (119)*
Durationfollow-up(months) 93 (76) 83 (115)
Desths 9 11
mean (s.d.) *ps 0.05 (BP= bloodpressure)
In Group 1, aeeociatad chronic renal disease (pyelonephfitia, glomeru-
Ionephritie)was present in 8. In Group 2, the underlying cauees of MHT were
essential hypertension (n = 9), chronic renal diseasa (4), Corm’s syndrome
(1) and phaeochromocytoma (l). There was no statistically significant differ-
ence in median survivai between Groups 1and2 (96 VS47monthe, Lee-Deeu
statietic = 0.75, p = 0.3S). Commoneet causes of deathe were renal failure
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(5), stroke(4)and heartdisease(2). Ourfindingsdo not supportthe belief
that the tX is a commoncauseof MHTamongstwomenof childbearing
age,buta pasthistotyof hypertensionIn pregnancyis Impotiant.Thelatter
patientsalsohavea longerdurationof priorhypertensionandpoorerrenal
functionat follow-up.
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754-6 DoesRenalFunctionImproveFollowingDiagnosis
of MellgnantPhaseHypatiension?
G.Y.H.Lip,M. Beavers,D.G.Beevers.UniversityDepartmentof Medicine,
CityHospital,Blrmlngham,England
ToInvestigatethehypoth~is whetherrenalfunotionimprovesfollowingdiag-
nosisof malignantphaaehypertension(MHT),westudied187patientswith
MHT(117male,meanage49.0years,s.d 13.2);73.0%(136/187)patients
hadan initialserumcreetinine(Cr) <300 wmolfl.Aftera medianfollow-up
of 53months(IQR15-103),51.6%(9W187)patientsdemonstrateda risein
serumCr.Patientswithan initialserumCr -=300wmol/1(Group1, n = 136)
wereoomparadwiththosewithCr>300 mmoWl(Group2, n=33); andthose
withan overallrfaein serumCr (GroupA, n = 38)werecomparedto those
withnorfseor a fallat follow-up(GroupB,n =91).
Results:mean@d.)
GrouP1 Group2 GroupA &ouP B
Aoe fV6WS) 49.5 [t4.o) 4s.s(10.3) 49.8(13.5) 4s.9 (13.0).g- ., .,
DurstfonofpriorHT(mths) 30.8 (58.3j 27.3(45.0) 33.6 (57.0) 25.6(54.5)
Inftfalurea (mmo!41) S.4 (3.7) 27.4 (16.S)” Io.e (9.7) 13.7 (12.5)
Initialcraatlne (Cr) (~mofll) 153 (58.6) 665 (450” 204 (155) 31s (399)+
SW atpraaan~tlon (mmHg) 230.0 (27.1) 328.8 (30.S) 230.1(29.2)229.3(25.8)
DBP at fxesentatlon(mmHg) 143.1 (19.6) 144.S (16.5) 143.8(20.3) 143,0 (17.4)
Follow-upurea (mmolrl) 11.7 (10.0) 29.7 (19.2)- 17.s (1s.5) 11.5 (8.7)+
Follow-upCreatinine (pmolll) 243 (295) 678 (333)* 409 (405) 223 (214)+
Follow-uPSBP (mmHg) 150.1 (30.5) 1s0.5 (3S.9)+ 170.0 (32.8) 156.0 (32.2)+
Fdlow-up DBP (mmHg) 95.6(17.3) 103.4(15.7)”” 100.2 (17.4) 93.0 (17.6)+
Follow-upduration(mtha) 70.1 (58.6) 33.4 (48.1)’ 61.9 (59.0) S4.4 (57.9)
(55P, DBP = systollc,diestollcbloodpressure) *P < O.IXM,‘p -=0.01, **p <0.05
Patients withmildinitialrenalImpairment(Group1)hadIowerserumurea,
CrandBPsatfollow-up,whancomparedto patientswithrenalimpairmentat
presentation(Group2). InGroup2, therewasnochangeinfollow-upserum
ureaor Cr whencomparedto initial levels(pairedt-test,p = NS).In Group
1,therewasamarkeddeteriorationin renalfunctionat follow-up(meanrise
in serum Cr SO #moVt, Seruiw urea 3.3 mmolll; both p < 0.0001). Group2
patientshada lowermediansurvivalcomparedwithGroup1 (15monthsvs
59months,Lae-Deaustatistic=15.4,p=0.0001).Patientswithdeteriorating
renalfunction(GroupA) had higherinitial serumCr levelsand follow-up
BPswhencomparedto GroupB.Wesuggestthat renalfunctioncontinues
to deterioratein patientswith MHT,despiteimprovedBPcontrolat follow-
UP.Patientswithestablishedrenalimpairmentat presentationdemonstrate
littleimprovementin renalfunction,poorerBPcontrolandreducedsurvival.
Carefulmonitoringof renalfunctionandBPisthereforemandatory.
El755 PharmacologicInterventionsfor MyocardialIschemiahnfarction
Tuesday,March 18, 1997, 2:00 p.m.–3:3Op.m.
AnaheimConventionCenter,RoomB2
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El7551 AmlodaronaReduceaMortalityin PostInfarctionPatientswithDepressedEjeotionFractionand
IncreasedHeaftRate
M. Malik,A.J.Carom,D.G.Julian,G.Frangin,M.J.Janse,P.J.Schwartz,
P.Simon,for the EMIATinvestigator.St.George’sHos@a/Medica/
School,London,England,SanofiRachercha,MontpelliecFrance
Thersautteof the EMIATtrialhaveshowna significantreduotionof arrhyth-
mia cardiacdeathsin post myocardialinfarctionpatients<75 yearswith
Ieflventricularejectionfraction(LVEF)s 40%but no radustionin ail cause
mortalitywasobaewed.Thiestudyexaminedthe potentialbenefitof Amio-
dareneinptswithbothreduoedLVFEandsignificantlyincreasedmeanheart
ratein baseline24-hourHelterrecordings.BaselineHelterrssordingswere
availablein 1181EMIATpts,a meannormal-to-normalRRintervals 850ms
(meansinusrhythmheartrate>--92 bpm)waspresentin74pts(20female,
meanage80.4& 9.9years).Of these,36 and38 werein the Amiodarone
andPlacebogroup,respectively.IntheAmiodaroneandPlacebogroupwith
increased 24-hour heart rate, there were 10 and 17deathsduringthe2 year
follow-up,respectively(27.8%vs447%). Cumulativesurvivorcufvesof pa-
tientswithincreasedmeanheartrateshowedclearseparation(Fig.:full line
= Amiodarone group,dashedline= Placebogroup)butbecauseof thesmall
numberof eventsin thesegroupsfailedto reachstatisticalsignificance.
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The resultsof this studysuggestthat Amiodaronemight be of benefit
to post-infarctionpatientswithreducedLVEFandseriouslyincreasedmean
heartrate.
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~755-21Tf’teEffectofAzithrcwttycinin Post-Myocardial
Infarction (Ml) Patients With Elevsted Ch/wnydia
pneumoniaeAntibodyTltres
S.Gupta,E.W.Leatham,D.Barrington,M.Mendall,N. Ireson,J. Tooze,
D.Bevan,A.J.Carom,J.C.Kaski.St George’sHospital,London,UK
Ch/an@iapteumoniae(Cp)infestionmayplaya role in atherogenesisby
up-regulatingrnonosyticactivationandInflammatorymediators.We investi.
gatedwhetherAzlthromycln(Az)antlblotlctherapyinpeat-Mlpatientsaltered
Cpantibodytitrea ndInflammatoryandprocoagulantmarkers.200maleaur-
vlvorsofMl(meanage60+ 7yeara;Ml >6 monthsprevious)werescreened
forelevatedCptitres(lgG> 1/84)usingthemlcroimmunofluorescencet st.
60 eligiblepatientswererandomisedintoa double-blindprospectivestudy
and rsceiveda 3-daycourseof AZ(500mg/day)or placebo(P).A fufther
blindedooureeof Azor P wasgivenafter3 monthsto 45 of the original60
patients.Bloodsamplesweretakenat baseline,1,3 and6 monthsandthe
markers measured included monocyte tissue factor (MTF)and CDllb ex-
pression (flow cytometric, MESF unita), total Ieutxqte count (WCC), aerum
naopterin, fibrinogen, Factor Vlla and C-reactive protein levels. No signifi-
cant differences werenotedin anyof the markersin eitherAzor P groupet
baseline,1 or 3 months.At6 monthsthe sub-groupof patientsrandomised
to doubleAz therapy(at baselineandagainat 3 months,GroupAZAZn =
11)showeda significantfall in totalMTFandCDllb comparedto the sub-
groupof patientsreoeivingplacebo(GroupPP,n = 10)only (mean+ SEM,
AMTF:–20.3 + 11.5vs +14.6+ 11.1,p = 0.04;and ACDllb: -2.7 + 1.2
vs+1.6+ 0.9,p = 0.01).RepeatCpserologyat 6 monthsshowedthat5/11
(45%)AZAZpatients(comparedto 0/10PPpatients)hada significantdrop
in Cptitre(p= 0.04).These5 patientsalsohada fall in WCCandneopterin
(neop/creatinine)comparedtothe16patientswithunchangedtitres(AWCC:
-1.2 + 0.6 vs 0.1 + 0.2 x IOg/L,p = 0.05;and Aneop/creat:-3.6+ 2.3va
+0.8?C0.5nmol/umol,p = 0.03).Conclusion:Azithromycintherapyreduces
monocyteactivationandCpantibodyfitresin Post-Mlpatients.Theeffectof
therapyonthe incidenceof futurecardiaceventsis beingexamined.
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1755-31Italianmulticenterstudyof ni~orandik~afetyand
efficacyof twodossregimensinetableangina
pactorispatients
G.Specchia,M.Chiariello,B.Magnani,A.Zanchetti,M. Bona.Univeraitias
of Pavia,Naples“Fedetico1/”,Bologna,Milan,ltal~ BrsccoS.P.A.,Milan,
Italy
Nimrandil (iV/CJis a potassiumATP-channelactivatorwith a nitrate like
activity Monotherepywith 10 to 20 mg bid of NIC has beenfound to be
efficaciousin stabieanginapaotorispatients.HoweverthetherapywithNIC
is associatedwithsomeincidenceof headacheas othervasodilators.Aim
of our double-blind,parallelgroupstudywasto comparethe incidenceof
adverseevents(AE),andparticularlyof headache,in twodoseregimensof
NICin patients(@) withetableangina.NICwasadministeredfor 6 weeka
in monotherapyat thedoseeof 5, 10,20 mgbid (A)or 10,20,20 mgbid (6I
(2weekaforeachdoseievei).Anadditionalaimof thestudywasto evaluate
efficacyof NICat eachdoseused.Aftera weekof wash-outand a weekof
placeborun-in,172patients(63A-69B)withreproducible xercisetolerance
test(ET7)wererandomised.Every2 weekssafetyandefficacy(ETT)were
